



CANCER CARE AT THE CROSSROADS

 **NY - April 1, 2022**

A One-Day International Summit on Innovation, Clinical Benefit and Cost

Meet the Sponsors



8:00am – 8:20am

Welcome and Opening Remarks

Setting the stage for the day



TOM MANIATIS, PHD

Scientific Director and CEO
New York Genome Center



MIKE MEYER

President
Meyer Consulting



MICHAEL DOWLING

President and CEO
Northwell Health

Opening Remarks

8:20am – 9:35am

Round Table 1

Cancer Care through the Lens of Health Plans, Academic Centers, Pharma and Provider Groups
What Has Happened in the Last 12 Months



Moderator

MACE L. ROTHENBERG, MD

Former Chief Medical Officer
Pfizer, Inc



Panelist

CLIFFORD HUDIS, MD

Chief Executive Officer
American Society of Clinical Oncology (ASCO)



Panelist

JEFFREY LE BENDER, MD, FACS

Executive Chairman
Summit Health



Panelist

MICHAEL DOWLING

President and CEO
Northwell Health



Panelist

CAROL PEDEN, MB ChB, MD, FRCA, FFCIM, MPH

Executive Director, Clinical Quality
Blue Cross Blue Shield Association

Round Table 1

Program

Round Table 2

9:35am – 10:50am

Round Table 2

The Future of Cancer Science



Moderator

JAMES L. GULLEY, MD, PHD

Director, Medical Oncology Service
Chief, Genitourinary Malignancies Branch
National Cancer Institute



Panelist

**DAVID A. TUVESON,
MD, PHD, FAACR**

Director, Cancer Center and Roy J. Zuckerberg
Professor, *Cold Spring Harbor Laboratory*
President, *AACR*



Panelist

**VALI A. PAPADIMITRA-
KOPOULOU, MD**

Vice President, Head of Clinical
Development, Global Product
Development, *Oncology Pfizer*



Panelist

**ALEXANDER M. M.
EGGERMONT, MD, PHD**

Chief Scientific Officer, Board of Directors
Professor Clinical & Translational
Immunotherapy, *UMCU, Utrecht University*



Panelist

**STEPHEN ALBERT
JOHNSTON**

CEO, *Calviri, Inc.*
Director, *Center for Innovations in
Medicine, ASU Biodesign Institute*

10:50am – 11:00am

Break

Round Table 3

11:00am – 12:15pm

Round Table 3

Improving Patient Outcomes and Addressing
Health Disparities in Cancer Care



Moderator

STEVEN PESKIN, MD

Executive Medical Director
*Horizon Blue Cross Blue Shield
New Jersey*



Panelist

KIMYATTA WASHINGTON

Vice President, *Oncology Services,
RWJBarnabas Health, Central Region and
Rutgers Cancer Institute of New Jersey*



Panelist

ALAN BRYCE, MD

Chair, Division of Hematology
and Medical Oncology,
Mayo Clinic



Panelist

RICHARD SULLIVAN, MD, PHD

Director, *Institute for Cancer Policy*
Professor of Cancer and Global Health,
King's College London



Panelist

THOMAS JACKIEWICZ, MPH

President, *University of Chicago
Medical Center*
Chief Operating Officer, *UChicago
Medicine Health System*

1:30pm – 2:45pm

Round Table 4

The Challenges Facing Health Plans, Providers and Governments in
Financing Innovative Cancer Treatments



Moderator

JON ROCKOFF

Health Business Editor and Deputy
Coverage Chief for Health and Science
The Wall Street Journal



Panelist

GLEN STETTIN, MD

Senior Vice President and
Chief Innovation Officer
Evernorth



Panelist

JOANNE M. CONROY, MD

President and CEO
*Dartmouth-Hitchcock and
Dartmouth-Hitchcock Health*



Panelist

DAVID P. CLEARY, MPH

Staff Director
*U.S. Senate Committee on Health,
Education, Labor, and Pensions*



Panelist

ARIEL DORA STERN, PHD

Poronui Associate Professor
of Business Administration
Technology & Operations Management
Harvard Business School

Round Table 4

2:45pm – 3:00pm

Break

3:00pm – 4:15pm

Round Table 5

AI and Analytics in Oncology



Moderator:

HAL PAZ, MD, MS

Executive Vice President, Health Sciences
Stony Brook University



Panelist

LILY PENG, MD, PHD

Director, Product Management
Health AI, Google Health



Panelist

KETAN PARANJAPE, PHD

Vice President, Diagnostic
Information Solutions
Roche Diagnostics Corporation



Panelist

DAVID A. JAFFRAY, PHD

Sr. VP & Chief Technology and Digital Officer
Professor, Radiation Physics and Imaging Physics
UT MD Anderson Cancer Center



Panelist

DAN AVI LANDAU, MD, PHD

Core Faculty Member
New York Genome Center

4:15pm – 4:30pm

Closing Remarks



JACQUE SOKOLOV, MD

Chairman and CEO
SSB Solutions



MIKE MEYER

President
Meyer Consulting

Panelist Bios Follow







ALAN BRYCE, MD

Chair, Division of Hematology and Medical Oncology
Mayo Clinic

Dr. Alan Bryce is a consultant in the Division of Hematology and Oncology, Department of Internal Medicine at Mayo Clinic in Arizona and serves as chair of the division. He is also chair of the Genitourinary Disease Group. He holds the academic rank of associate professor of medicine, Mayo Clinic College of Medicine. He joined the staff of Mayo Clinic in 2011.

Dr. Bryce earned his B.S. degree in biochemistry at University of California, Los Angeles, and his M.D. degree at Finch University of Health Sciences, Chicago Medical School. He completed a residency in internal medicine and a fellowship and chief fellowship in hematology/oncology at Mayo Graduate School of Medicine.

Dr. Bryce's primary focus is on prostate cancer and testicular cancer. His research centers on developing new approaches to the treatment and cure of cancer. This includes developing new treatments through clinical trials and better understanding of cancer evolution through interrogation of the genetic mutations of individual cancer cells. His work includes studies of immunotherapy, genetically targeted therapies, hormone therapy, injectable radiotherapy, and chemotherapy. Dr. Bryce is committed to health equity and patient centered care. He believes that individualized medicine starts with tailoring all treatment to the patient's goals and values.



DAVID P. CLEARY, MPH

Staff Director, *U.S. Senate Committee on Health, Education, Labor, and Pensions*
Principal Advisor to Sen. Richard Burr of North Carolina

David P. Cleary is the Republican Staff Director for the United States Senate Committee on Health, Education, Labor, and Pensions, serving as the principal advisor to Sen. Richard Burr of North Carolina, the Ranking Republican Member. David has been the Staff Director since 2013 under Chairman Lamar Alexander, and was previously also Chief of Staff to United States Senator Lamar Alexander where he led the combined HELP committee staff and the Alexander personal office on Alexander's legislative agenda.

Prior to joining the Senate, David worked for the House Education and Workforce Committee for Chairman John Boehner (R-Ohio on disability policy. David started his career at the U.S. Department of Education, working on elementary and secondary education and special education issues for several years. David, and his wife Marci, have one daughter.



JOANNE M. CONROY, MD

President and CEO
Dartmouth-Hitchcock and Dartmouth-Hitchcock Health

Dr. Conroy is a committed leader in advancing equity in the workplace. She is a co-founder of "Women of Impact," a nonpartisan group of 60 female health care leaders representing all sectors of the health care industry across the nation. She was also instrumental in D-HH becoming one of the founding signatories of the TIME'S UP Healthcare initiative, which aims to increase safety and gender equity in the health care industry. She was named one of the "100 Most Influential People in Healthcare" by Modern Healthcare in 2018 and 2020.

Prior to joining D-H and D-HH, Dr. Conroy served as CEO of Lahey Hospital & Medical Center in Burlington, MA, and as Chief Health Care Officer for the Association of American Medical Colleges in Washington, DC. She has also served as Chief Medical Officer, Vice President of Academic Affairs and Executive Vice President of the Atlantic Health System based in Florham Park, NJ, and as President and Chief Operating Officer for the Morristown Memorial Hospital (now called Morristown Medical Center) in Morristown, NJ. She held several academic and administrative leadership positions at the Medical University of South Carolina (MUSC), including President of the MUSC medical staff, Associate Vice President for Medical Affairs, Executive Medical Director and Senior Associate Dean of the MUSC College of Medicine.

Dr. Conroy received her undergraduate degree in chemistry from Dartmouth College and her medical degree from MUSC, where she completed her residency in anesthesiology, serving as Chief Resident for one year.



MICHAEL DOWLING

President & CEO
Northwell Health

Michael Dowling is one of health care's most influential voices, taking a stand on societal issues such as gun violence and immigration that many health system CEOs shy away from. As president and CEO of Northwell Health, he leads a clinical, academic and research enterprise with a workforce of more than 76,000 and annual revenue of \$14 billion.

Mr. Dowling has received numerous awards, including the Ellis Island Medal of Honor and a number of honorary degrees from Fordham University, University College Dublin (Ireland) and the prestigious Queen's University Belfast. In 2017, he served as the Grand Marshal of the St. Patrick's Day Parade in NYC and he chairs the Institute for Healthcare Improvement.

Prior to joining Northwell in 1995, Mr. Dowling served in New York State government for 12 years, including leadership roles as director of health, education and human services, commissioner of social services, deputy secretary and a chief adviser to former Governor Mario Cuomo. Earlier, he was a professor of social policy and an assistant dean of Fordham's Graduate School of Social Services.



ALEXANDER EGGERMONT, MD, PHD

Chief Scientific Officer, Board of Directors
Professor, Clinical & Translational Immunotherapy, *UMCU, Utrecht University*
Editor in Chief, *European Journal of Cancer*

Full Professor of Oncology (2012-20) (Classe Exceptionnelle) at the Paris-Sud University in Paris, France. Past Director General Gustave Roussy Cancer Institute. Full Professor of Surgical Oncology (2003-2016) as well as Endowed Professor of International Networking in Cancer Research (2011-2020) at Erasmus University MC Rotterdam. He holds the Joseph Maisin Chair in Oncology at Catholic University of Louvain in Belgium. PhD in tumor immunology at Erasmus University Rotterdam (1987) and is a Fellow of the NCI Surgery Branch, USA.

Specialties: His clinical specialties include immunotherapy, melanoma, sarcoma and general drug development. He is a past Chair of the EORTC Melanoma Group and current Chair of the Adjuvant Therapy Committee EORTC MG. His basic research experience is in tumor immunology, advanced in vivo imaging models, drug development.

Scientific Output: is the author or co-author of > 800 peer-reviewed publications, book chapters and monographs. More than 35 PhD theses have originated in his clinical, translational and basic research programs at the Erasmus University MC Rotterdam. H-Index: 100; > 50000 citations

International Functions:
DKFZ-NCT/Deutsche Krebshilfe:
Coordinator German National Center for Tumors Network 2020
European Academy of Cancer Sciences: President, 2010-2020
Cancer Core Europe President – 2014-2020 ECCO: Past President EORTC: Past President
ASCO: Past Board Member (Surgery Chair) and JCO Editorial Board AACR: Past Deputy Editor of Clinical
Cancer Research (2001-2009) Deutsche Krebshilfe:
Chair International Jury for Comprehensive Cancer Centers Program 2008-2020
European Journal of Cancer: Editor-in-Chief since 2011

Societal Awards:
Presidential Medical, Kazakhstan (2014) Legion d'Honneur, France (2015)



JAMES GULLEY, MD, PHD

Chief, Genitourinary Malignancies Branch
Director, Medical Oncology Services
Center for Cancer Research National Cancer Institute,
National Institutes of Health

Dr. James Gulley is an internationally recognized expert in cancer Immunotherapy with a strong interest in prostate cancer. He graduated from Loma Linda University in California with a PhD in microbiology in 1994 and an MD in 1995. As part of this eight-year MD/PhD Medical Scientist Training Program he completed a dissertation on tumor immunology. Dr. Gulley completed his residency in internal medicine at Emory University in 1998, followed by a medical oncology fellowship at the NCI.

Since 1999 he has authored and run a variety of clinical trials at the NCI, serving as Principal Investigator or Associate Investigator on more than 200 trials including dozens of first-in-human studies. These innovative investigator-initiated studies involve the use of cancer vaccines and other immunostimulatory agents, and the combination of immunotherapy with other treatment strategies. In particular, he has played a central role in the clinical development of a number of vaccines and antibodies including avelumab (Bavencio) and bintrafusp alfa. His clinical studies led to the approval of avelumab in 2017.

Dr. Gulley has authored more than 300 scientific papers and book chapters, edited four books, and has made hundreds of presentations at national and international meetings.



CLIFFORD A. HUDIS, MD, FACP, FASCO

Chief Executive Officer
*American Society of Clinical Oncology
Association for Clinical Oncology*

Dr. Hudis is the Chief Executive Officer of the American Society of Clinical Oncology (ASCO). He also serves as the Executive Vice Chair of its Conquer Cancer Foundation and Chair of the Board of ASCO's CancerLinQ. Dr. Hudis previously served in a variety of volunteer and leadership roles at ASCO, including as its President during the Society's 50th anniversary year (2013-14).

Before coming to ASCO full-time, he was the Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City and Professor of Medicine at the Weill Medical College of Cornell University. As CEO of ASCO, Dr. Hudis is responsible for delivering on the board's strategic goals through education, research, and support for the delivery of the highest quality of care by the Society's nearly 45,000 members.



THOMAS JACKIEWICZ

President, *University of Chicago Medical Center*
Chief Operating Officer, *UChicago Medicine Health System*

Tom Jackiewicz is president of the University of Chicago Medical Center, a leading \$3B academic and community health system. He leads the clinical enterprise, including the integration of the patient care mission of the medical center with the education and research missions of the University of Chicago Biological Sciences Division.

Mr. Jackiewicz' career has focused on executing ambitious and broad transformation in academic environments and engaging physician leaders to drive organizational change. A strategic visionary, he has ushered in eras of substantial growth and improvement at academic health systems across the country. At University of Chicago Medical Center, he is securing approval to build a new \$633M cancer center, spearheading development of a northwest Indiana campus and leading a major collaborative of providers focusing on health challenges on Chicago's South Side.

During his tenure as CEO of Keck Medicine of USC, he grew University of Southern California's medical enterprise into a \$2.4 billion regional academic health system with internationally renowned physicians, care quality in the top quartile in the country and exceptional scientific research capabilities. In 2019 and 2020, Keck Hospital achieved a top 20 ranking on the U.S. News & World Report Best Hospitals Honor Roll.

Mr. Jackiewicz has also served in leadership roles at the University of California, San Diego Health System and Health Sciences, Columbia University Medical Center and Stanford University School of Medicine. He earned his master's degree from Columbia University and his bachelor's degree from the University of Georgia.



DAVID A. JAFFRAY, PHD

Sr. VP and Chief Technology and Digital Officer
Professor, Radiation Physics and Imaging Physics
UT MD Anderson Cancer Center

David Jaffray is a Senior Vice President and Chief Technology and Digital Officer at The University of Texas MD Anderson Cancer Center. He also is Professor of Radiation Physics with a dual appointment as professor of Imaging Physics. Recruited to MD Anderson in May 2019, Dr. Jaffray brings more than two decades of scientific expertise and proven skill as an innovator.

Before joining MD Anderson, Dr. Jaffray served as Executive Vice President for Technology and Innovation at the University Health Network (UHN)/Princess Margaret Cancer Centre in Toronto, Ontario. He led UHN's information technology transformation, designed the roadmap for digital transformation. He also served in several other leadership roles at UHN, including Vice Chair of Research for the University of Toronto's Department of Radiation Oncology, Founding Director of the STTARR Innovation Centre, and Founding Director of the Techna Institute for the Advancement of Technology for Health.

Dr. Jaffray holds multiple patents and has authored more than 275 peer-reviewed publications in topics related to cancer, including, the development of new radiation treatment machines, exploring the fundamental limits of imaging system performance, and the development of novel nanoparticle formulations for improved detection of cancer. He has an interest in commercialization and has led the development of a variety of commercial products, including software and hardware for safe, high-quality cancer care and the development of numerous radiation therapy technologies, including the development of cone-beam CT guided radiation therapy.



STEPHEN ALBERT JOHNSTON

CEO, *Calviri, Inc.*
Director, Center for Innovations in Medicine
Biodesign Institute, Arizona State University

Stephen Albert Johnston is CEO and cofounder of Calviri, Inc., a spin out of the ASU Biodesign Institute. Dr. Johnston's expertise includes drug targeting, vaccine technology, cancer treatment, and presymptomatic diagnosis of cancers through identifying the biosignatures of disease. His current work focuses on inventing technologies in biomedicine, with some successes. At Calviri, Inc. he is developing diagnostics for detection of cancer, including a simple chip-based blood assay for early diagnosis. As their objective is to end death from cancer with technologies that can be implemented worldwide, Calviri is also, more ambitiously, working to develop vaccines that prevent cancer. Importantly, Calviri products are designed to be priced so that anyone in the world can have access to them.

Dr. Johnston also serves as Director for the Center for Innovations in Medicine (CIM), Professor in the School of Life Sciences, and Director of the Biological Design Graduate Program at ASU's Biodesign Institute. The CIM focuses on innovative solutions to fundamental problems in biomedicine; the Center is unique in that it has brought together a group of interdisciplinary scientists who first identify a problem, analyze the physical economy basis of the related issues, and then propose an inventive solution. Current major projects are: 1) Cancer Eradication - developing a universal, preventative cancer vaccine, and 2) Health Futures – producing a diagnostic system that allows continuous monitoring of the health status of healthy people, thus advancing the revolution of presymptomatic medicine.

Dr. Johnston notably first cloned the Gal4 gene showing that proteins have separable functional domains. He also discovered the AAA proteins and their role in transcription. He was coinventor/innovator of pathogen derived resistance, organelle transformation, the "gene gun," genetic immunization, TEV protease system, expression library immunization, linear expression elements, synbodies, and immunosignaturing. He has authored over 150 journal articles, has over 20 patents, and has garnered over \$85M in grant support including large programs from DARPA, NIAID and NHLBI.



DAN AVI LANDAU, MD, PHD

Core Faculty Member
New York Genome Center

Dan A. Landau, MD, PhD, is a Core Faculty Member at the New York Genome Center. He holds a joint appointment as Associate Professor of Medicine in the Division of Hematology and Medical Oncology and the Department of Physiology and Biophysics at Weill Cornell Medicine. Dr. Landau and his lab study primarily human cancer which constitutes a unique phenomenon in evolutionary biology – 'reverse engineering' whereby cells rescind the multicellular contract and evolve to more closely resemble unicellular organisms. Importantly, the evolutionary plasticity of cancer imposes significant limitations on the potential of cancer therapies.

Dr. Landau's goal is to chart a roadmap of the basic dimensions that determine the course of cancer evolution, in order to devise therapies that directly anticipate and address tumor evolution. He has pioneered the study of intra-tumoral genetic and epigenetic diversity in patient samples to enable the study of cancer evolution in its natural environment.

Dr. Landau's work includes an artificial intelligence algorithm development to identify sparse cancer signals in blood sequencing to non-invasively monitor cancer response for therapeutic optimization. His work has been recognized with many honors, most recently a 2019 Weill Cornell Department of Medicine Young Investigators Award, a 2018 NIH Director's New Innovator Award, the inaugural ASPIRE (Accelerating Scientific Platforms and Innovative Research) Award from The Mark Foundation for Cancer Research, a Stand Up to Cancer Philip A. Sharp Innovation in Collaboration Award, the Pershing Square Sohn Prize for Young Investigators in Cancer Research, and a Lung Cancer Discovery Award from the American Lung Association.

Dr. Landau obtained his MD from Tel Aviv University. He then went on to receive his PhD from Paris Diderot University. Prior to joining the New York Genome Center, Dr. Landau was an Instructor of Medicine at Harvard Medical School, working at the Dana Farber Cancer Institute and the Broad Institute.



JEFFREY LE BENDER, MD, FACS

Executive Chairman
Summit Health

Dr. Jeffrey Le Benger is Executive Chairman of the board that governs Summit Health, the health care network formed by the 2019 merger of Summit Medical Group and CityMD. As Executive Chairman, Dr. Le Benger provides counsel and guidance to Summit Health's leadership and supports the ongoing successful execution of Summit Health's long-term strategic plan.

Prior to becoming Executive Chairman in October 2021, Dr. Le Benger served as Chief Executive Officer of Summit Medical Group since 1999 and of Summit Health since 2019. He is a visionary and thought leader in physician group practice management, value-based care, population health management and other timely issues that impact the quality and availability of health care.

During his decades of leadership, the century-old Summit Medical Group achieved unprecedented growth and success. After devising and refining a highly effective practice management and patient care model at Summit Medical Group Dr. Le Benger spearheaded the formation of Summit Health Management in 2014 to expand Summit's model via strategic partnerships and customized managed services contracts. In January 2018, Summit Medical Group Oregon – Bend Memorial Clinic in Central Oregon was established, affirming Summit's unique care model is customizable and nationally relevant.

In another significant milestone during his tenure as CEO, Summit Medical Group, one of the nation's premier independent physician-driven multispecialty medical groups, and CityMD, the leading urgent care provider in the New York metro area, merged to establish Summit Health, offering high-quality primary, specialty, and urgent care. Summit Health currently has more than 2,000 providers, 9,000 employees and over 200 locations in New Jersey, New York, and Central Oregon.

Dr. Le Benger earned his medical degree from New York Medical College and completed his residency at Mount Sinai Medical Center.

Panelist Bios



THOMAS MANIATAS, PHD

Evmin Family Scientific Director and Chief Executive Officer

New York Genome Center

Isidore S. Edelman Professor of Biochemistry and Molecular Biophysics
Columbia University

Dr. Maniatis leads the research and operational activities of the New York Genome Center (NYGC), which focus on the development of computational and experimental genomic methods and disease-focused research to better understand the genetic basis of cancer, neurodegenerative diseases, and neuropsychiatric diseases. He also directs NYGC's faculty, who lead independent research labs based at the Center. All of the core faculty members hold tenure-track joint appointments with one of the Center's member institutions. This arrangement has been a driving force in connecting the NYGC with its founder members.

Dr. Maniatis is recognized as one of the pioneers of modern molecular biology, having led the development of recombinant DNA methods and their application to the study of the mechanisms of gene regulation. He co-authored the definitive laboratory manual on genetic engineering, entitled the *Molecular Cloning Manual*, along with Joe Sambrook and Ed Fritsch in 1982. This three-volume manual, published by the Cold Spring Harbor Laboratory, set a standard for international dissemination of recombinant DNA methods. Dr. Maniatis' research has led to major advances in understanding the mechanisms of gene expression at the level of RNA transcription and splicing. His current research is focused on the role of single cell diversity in neural connectivity, and on the molecular mechanisms that underlie the neurodegenerative disease ALS (Lou Gehrig's Disease).

Dr. Maniatis' research contributions have been acknowledged by membership in the U.S. National Academy of Sciences and the U.S. National Academy of Medicine, and by numerous awards, including the Eli Lilly Research Award in Microbiology and Immunology, the Novartis Drew Award in Biomedical Research, the Richard Lounsbery Award for Biology and Medicine, and the Lasker Koshland Special Achievement Award in Medical Science. He has received honorary PhD degrees from the Cold Spring Harbor Graduate School, the University of Athens, and the Rockefeller University.



MIKE MEYER

Founder and President

Meyer Consulting

Mike Meyer is an entrepreneur, author, health care expert, and founder and host of the CCX Cancer Summit held each year in New York City. He is the President of Meyer Consulting. Early in the pandemic, he coauthored an op-ed in the *Wall Street Journal* titled *Medical Lockdown will Cause a Disease Surge*, which proved remarkably accurate. He is known for his work with leading health systems, academic medical centers and health care companies. Over the years, he has built or helped grow multiple health care companies.

Meyer founded Meyer Consulting in 2007 to offer healthcare organizations a consulting firm that has a unique business model encompassing executive search, strategic consulting, and human capital consulting. Meyer's current and former clients include Memorial Sloan Kettering Cancer Center, Mayo Clinic, Blue Cross Blue Shield Association, Horizon Blue Cross Blue Shield NJ, Pfizer, MD Anderson Cancer Center, Summit Medical Group, California Association of Health Plans, WIN Consortium for Personalized Cancer Medicine and numerous other academic centers, large providers, physician groups and other not-for-profit health care organizations.

Meyer's early career was as vice president in charge of the New York office of Amherst Associates, which went public in 1981. He subsequently became a senior partner in Witt Kieffer before founding Meyer Consulting in 2007. Meyer founded Cancer Care at the Crossroads (CCX) Summit in 2016. This one-of-a-kind event brings together senior health care executives from the US and international. In 2019 Meyer Consulting's executive search practice was acquired by Westwood & Wilshire, one of the premier firms in life sciences and technology.

Meyer was a board member of Summit Select, part of Summit Medical Group which merged with CityMD, creating one of the largest private physician groups in the U.S., with support from Warburg Pincus. He cofounded the Institute for Mental Health Research (www.imhr.org), and is a board member of the Human Health and Research Foundation (<http://hhfrf.org>). He has been widely quoted on healthcare, oncology, mental health and retiree topics in healthcare and business publications. He is the author of *Catastrophic Illness and Catastrophic Health Insurance* published by the Heritage Foundation, and coauthor of *Destination Southwest, a Guide to Retiring and Wintering in Arizona*.



VALI PAPADIMI- TRAKOPOULOU, MD

VP, Head of Clinical Development

Global Product Development, Oncology
Pfizer

Dr. Vali Papadimitrakopoulou is recognized globally for her expertise in personalized genomics-driven cancer therapies, immunotherapies, translational research and cancer chemoprevention.

Vali joined Pfizer in September 2019 from the University of Texas MD Anderson Cancer Center, where she was an Endowed Professor of Medicine and Section Chief of Thoracic Oncology in the Department of Thoracic/Head and Neck Medical Oncology. She has led numerous clinical and translational research projects focused on the development of biomarker-based targeted therapies to overcome therapeutic resistance in advanced disease. Vali recently served as a member of the FDA's Oncologic Drugs Advisory Committee (ODAC) and as co-principal investigator on the Master Lung Protocol (Lung-MAP) study.

She has extensive experience leading the design and implementation of innovative clinical development programs in Oncology, managing multidisciplinary research teams, and spearheading collaborative efforts within and across the global Oncology community.

Vali received her medical degree from the University of Patras School of Medicine, completed residencies at Institut Gustave Roussy in Paris and Columbia Presbyterian Medical Center in New York and a fellowship at the MD Anderson Cancer Center. She is currently pursuing an Executive MBA at the Massachusetts Institute of Technology Sloan School of Management. She is the recipient of numerous awards and honors including, most recently, the 2018 Addario Lectureship Award from the Bonnie J. Addario Lung Cancer Foundation and MD Anderson Cancer Center's 2017 Irwin H. Krakoff Award of Excellence in Clinical Research. She is the lead author or co-author of more than 200 publications, including articles in the *New England Journal of Medicine*, *Nature* and *The Journal of Clinical Oncology*.



KETAN PARANJAPE, PHD

Vice President, Diagnostic Information Solutions
Roche Diagnostics Corporation, Roche Diagnostics

Dr. Paranjape is VP of Commercial Business Operations at Roche. He is also a VP in the Roche Information Solution group chartered with harnessing the power of data, diagnostics and other critical information to support better clinical decisions.

He holds MS degrees in Electrical Engineering and Computer Sciences from the University of Wisconsin, and an MBA from the University of Oregon, where he was the class valedictorian. He also completed the Stanford Executive Program as well as coursework in Healthcare Management at the Harvard School of Public Health.

Dr. Paranjape holds a PhD in applying Artificial Intelligence to Healthcare from the Amsterdam University Medical Center. He is an Honorary Research Fellow at the Imperial College London, and Technical Advisor in Artificial Intelligence at Lee Kong Chian School of Medicine Singapore.

Dr. Paranjape is a certified paramedic and resides in Indianapolis, Indiana with his wife and son.



HAROLD L. PAZ, MD, MS

Executive Vice President, Health Sciences
Stony Brook University

Dr. Harold L. Paz is a nationally renowned healthcare leader with a unique combination of expertise in both academic medical centers and a Fortune 50 company. As the first Executive Vice President of Health Sciences at Stony Brook University, Dr. Paz works collaboratively with academic, hospital and clinical leadership and community partners to ensure the continued development of Stony Brook Medicine as a premier academic medical center and health system. Stony Brook Medicine includes five health sciences schools, four hospitals and more than 230 community-based healthcare settings throughout Long Island.

Prior to this role, Dr. Paz was the first executive vice president and chancellor for health affairs at The Ohio State University and chief executive officer of the OSU Wexner Medical Center. Before joining OSU, Dr. Paz was executive vice president and chief medical officer at Aetna CVS Health where he led clinical strategy and policy at the intersection of all of Aetna's domestic and global businesses. Prior to joining Aetna in 2014, Dr. Paz served as president and CEO of the Penn State Hershey Health System, senior vice president for health affairs at the Pennsylvania State University, and dean of its College of Medicine for eight years. Before his appointment at Penn State, he spent eleven years as dean of the Robert Wood Johnson Medical School and CEO of the Robert Wood Johnson University Medical Group. Previously, Dr. Paz was adjunct professor of internal medicine at the Yale University School of Medicine and clinically active in pulmonary medicine at the West Haven (CT) VA Hospital.

Dr. Paz received his bachelor's degree from the University of Rochester, a master of science in life science engineering from Tufts University, and his medical degree from the University of Rochester School of Medicine and Dentistry. He completed his residency at Northwestern University, where he served as chief medical resident. Dr. Paz was a Eudowood Fellow in pulmonary and critical care medicine at Johns Hopkins Medical School. In addition, he was a post-doctoral fellow in environmental health science at Johns Hopkins School of Hygiene and Public Health.



CAROL J. PEDEN, MB ChB, MD, FRCA, FFCIM, MPH

Executive Director, Clinical Quality
Blue Cross Blue Shield Association

Dr. Carol Peden is Executive Director of Clinical Quality for the Blue Cross Blue Shield Association (BCBSA), a national federation of 34 independent Blue Cross Blue Shield companies covering care for 110M Americans. As Executive Director, Dr. Peden provides clinical quality leadership and expertise for BCBS companies and represents the Blue System with key external stakeholders to promote quality improvement, performance, and measurement. She is a member of the National Academy of Science, Engineering and Medicine roundtable on quality of care for people with serious illness.

Dr. Peden is an internationally recognized physician leader, academic and writer who has designed and led complex quality improvement projects around the world. Prior to joining BCBSA in 2021, Peden was executive director for health system innovation at Keck Medicine of USC, the nationally ranked medical enterprise of the University of Southern California, and in prior roles in the United Kingdom, developed patient safety collaboratives and quality goals for 13.5 million people through NHS England.

Dr. Peden holds academic appointments as Adjunct Professor of Clinical Anesthesiology at the University of Pennsylvania, at the University of Southern California and at the University of Bath (UK) Center for Healthcare Innovation and improvement. She gained her quality expertise with the Institute of Healthcare Improvement (IHI), and with the Health Foundation in London. Dr. Peden is dually accredited in anesthesiology and intensive care medicine and has a medical degree and research doctorate from the University of Edinburgh (UK). She also has a master's degree in public health from the Harvard T. H. Chan School of Public Health and was named as their Public Health Innovator of the Year in 2016.



LILY PENG, MD, PHD

Director, Product Management, Health AI
Google Health

Dr. Peng is a physician-scientist and product manager for Google Health. Her team works on applications of deep learning to increase the availability and accuracy of care. Some of her team's recent work includes building models to detect diabetic eye disease, predict cardiovascular health factors from retinal images, detect breast cancer and lung cancer from screening scans.

Before Google, Dr. Peng was a product manager at Doximity and a co-founder of Nano Precision Medical, a drug delivery device start-up. She holds a B.S. with honors and distinction in Chemical Engineering from Stanford University and a MD/PhD in Bioengineering from the University of California, San Francisco.



STEVEN R. PESKIN, MD, MBA, MACP

Executive Medical Director, Population Health
Horizon Blue Cross Blue Shield of New Jersey

Steven R. Peskin, MD is the Executive Medical Director, Population Health at Horizon Blue Cross Blue Shield of New Jersey. His expertise encompasses physician leadership, population health management, clinical and operational performance improvement in health care, medical education and scientific communications. He has been one of the driving forces for the creation of and successful maturation of value based models in New Jersey.

Dr. Peskin is an Associate Clinical Professor in the Department of Medicine at Rutgers Robert Wood Johnson Medical School. He is a clinical preceptor at The Eric B. Chandler Clinic for interns and residents in Internal Medicine. Dr. Peskin assists with the Population Health and business of medicine training for the Rutgers RWJ Internal Medicine physicians in training.

Dr. Peskin received his bachelor's degree from The University of North Carolina Chapel Hill and medical degree from Emory University School of Medicine. He completed residency at Saint Elizabeth's Medical Center in Boston and holds an MBA from the Sloan School of Management at Massachusetts Institute of Technology.



JONATHAN D. ROCKOFF

Health Business Editor and
Deputy Coverage Chief for Health and Science
The Wall Street Journal

Jonathan D. Rockoff is the Health Business Editor at The Wall Street Journal, as well as its Deputy Coverage Chief for Health and Science. Based in New York City, he edits a group of reporters that write about pharmaceutical companies, health insurers and hospitals, while helping oversee science, medicine and public-health reporting. Previously for the newspaper, Jonathan reported on the pharmaceutical and biotechnology industries. He was a member of a team of reporters that was a finalist for the Pulitzer Prize for their coverage of drug pricing. Jonathan has also worked at The Baltimore Sun and The Providence Journal. He is a graduate of Princeton University and the University of Virginia School of Law.



MACE ROTHENBERG, MD

Former Chief Medical Officer
Pfizer, Inc

Mace L. Rothenberg, MD is a physician-executive with more than 30 years of experience in drug development, translational research, and risk-benefit assessment. Dr. Rothenberg served as Chief Medical Officer of Pfizer from 2019 to 2021. Prior to that role, Mace was Pfizer's Head of Clinical Development & Medical Affairs for Oncology from 2008 to 2016, and Chief Development Officer for Oncology from 2016 to 2018. During that time, his organization developed and obtained regulatory approval for 11 new cancer medicines including first-in-class medicines Ibrance (palbociclib) for patients with HR+/HER2- advanced breast cancer and Xalkori (crizotinib) for patients with ALK+ non-small cell lung cancer. Prior to joining Pfizer, Dr. Rothenberg was Professor of Medicine at Vanderbilt University and Ingram Professor of Cancer Research at the Vanderbilt-Ingram Cancer Center from 1998 to 2008. From 1991 to 1998, Mace was Associate Professor of Medicine at the University of Texas Health Science Center at San Antonio and Executive Officer of the Southwest Oncology Group.

Dr. Rothenberg is the recipient of the first Craig Saxton Lifetime Achievement Award from Pfizer, the Lane W. Adams Quality of Life Award from the American Cancer Society and the Statesman Award from the American Society of Clinical Oncology. He is board-certified in Internal Medicine and Medical Oncology and is a Fellow of the American College of Physicians and the American Society of Clinical Oncology. Mace serves on the Board of Directors for Aulos Bioscience, Tango Therapeutics, and Surrozen, as well as the Board of Overseers for the Vanderbilt-Ingram Cancer Center, the Alumni Board of Governors of the NYU Grossman School of Medicine, and the Board of Visitors for Basic Sciences at the Vanderbilt University School of Medicine.



JACQUE J. SOKOLOV, MD

Chairman and CEO
SSB Solutions

Dr. Jacques Sokolov is Chairman and Chief Executive Officer of SSB Solutions, Inc., a U.S based, diversified healthcare management, development and financial services company currently operating in over 20 states.

Following his formal training as an academic cardiologist, Dr. Sokolov started his career as Vice President for Healthcare and Chief Medical Officer for Southern California Edison Corporation (NYSE:EIX). He currently serves, or has served, in multiple board capacities for public companies including Hospira (NYSE: HSP), MedCath (NASDAQ: MDTH), and PhyAmerica (NYSE: ERDR); private companies including GlobalMed, Zoonie(SMG), MyHealthDirect, NeuLife Neurological Services (NeuLife), Calviri, AKOS, the Trill Project; and SSB wholly owned companies and nonprofit organizations including Phoenix Children's Hospital, the Health Futures Council at ASU, the Executive Committee of the Board of Councilors for the USC School of Pharmacy, the National Health Foundation, the American College of Medical Quality, the National Fund for Medical Education, and the National Business Group on Health and the White House Health Project.

Dr. Sokolov received his BA and MD Degree from the University of Southern California. He completed his internal medicine residency at the Mayo Graduate School of Medicine and his fellowship in cardiovascular diseases from the University of Texas-Southwestern Medical School. He previously held and currently holds academic appointments and advisory board responsibilities in the Schools of Medicine, Business and Public Health at Harvard, the Massachusetts Institute of Technology, the University of Pennsylvania, the University of California, Los Angeles, and the University of Southern California.



ARIEL DORA STERN, PHD

Poronui Associate Professor of Business Administration
Technology and Operations Management Unit
Harvard Business School

Ariel Dora Stern is Poronui Associate Professor of Business Administration in the Technology and Operations Management Unit at Harvard Business School, where she teaches the MBA course "Transforming Health Care Delivery." Ariel's research focuses on technology management and innovation in health care. Her projects consider the regulation, strategy, and economics of health care, with a focus on understanding the drivers of new product development among firms and the determinants of how new medical technologies are adopted and used in practice. She is a faculty affiliate of *Ariadne Labs*, a joint center for health systems innovation at Brigham and Women's Hospital and Harvard T.H. Chan School of Public Health and the Harvard-MIT Center for Regulatory Science.

Dr. Stern's research has been cited by Bloomberg, The New York Times, and National Public Radio. She received her Ph.D. from Harvard, where she was a National Bureau of Economic Research Predoctoral Fellow in the Economics of Health and Aging. She holds an undergraduate degree in economics from Dartmouth College, where she was a Presidential Scholar and a two-time U.S. national collegiate figure skating champion. From 2020-2021 Ariel served as the Director for International Health Care Economics at the Health Innovation Hub, the independent think tank of the German Federal Ministry of Health. She is a member of the Scientific Advisory Board of the German Society for Digital Medicine and advises health care start-ups.

Panelist Bios



GLEN STETTIN, MD

Chief Innovation Officer, *Evernorth*

Dr. Glen Stettin is a champion for new solutions to our clients' and patients' biggest healthcare challenges — affordability, poor care and outcomes, poor experiences and the inequity that amplifies these challenges for members of disadvantaged and marginalized communities. For more than 25 years, Dr. Stettin has been leading innovation, clinical and technical development, and advancing analytic approaches for understanding these big challenges and prompting action on behalf of the clients and patients of the health services businesses that have become Evernorth.

As Chief Innovation Officer, Dr. Stettin applies his expertise in diagnostic and treatment strategies, the behavioral sciences and data science to address the most complex and challenging issues in the coverage and delivery of quality health care. Dr. Stettin's team includes the leaders of the Evernorth Research Institute, which focuses on deeply understanding the big healthcare challenges and approaches to solving them, Evernorth's chief patient and physician experience officers, the heads of our advanced data and analytic capabilities and services, and Evernorth Labs, which brings together more than 200 experts, including physicians, nurses, pharmacists, data scientists and software engineers, across sites in three cities, designed for innovation and collaboration, to focus on solving client and patient pain points, through rapid prototyping, in-house development and partnerships with clients and industry innovators.

Dr. Stettin joined the Cigna Corporation in 2018 through the acquisition of Express Scripts, where he had served as senior vice president & chief innovation officer. He came to Express Scripts in 2012 with the acquisition of Medco, where he served as chief medical officer and, for 17 years, in leadership positions in nearly every corporate function with exception of finance, legal and human resources.

Dr. Stettin completed his residency in internal medicine at the University of California, San Francisco, where he also served as medical chief resident and assistant chief of the medical service, Moffitt Hospital, fellow in cardiology and Robert Wood Johnson Clinical Scholar (UCSF/Stanford). He earned his medical and bachelor's degrees through the joint accelerated program of the Medical College of Pennsylvania and Lehigh University.



RICHARD SULLIVAN, MD, PHD

Director, *Institute for Cancer Policy*
Professor of Cancer and Global Health, *King's College London*

Dr. Richard Sullivan is Professor of Cancer and Global Health at King's College London, Director of the King's Institute of Cancer Policy and co-Director of the Conflict and Health Research Group. His global cancer research covers cancer systems strengthening, financing, political economy, global radiotherapy, social welfare and cancer care in conflict. He also leads major programs on conflict and health across the Middle East, global health security & intelligence and a wide range of clinical areas, particularly blast and ballistic injuries. Dr. Sullivan qualified in medicine and trained in surgery (urology) gaining his PhD in Biochemistry from University College London.

Dr. Sullivan was Clinical Director of Cancer Research UK between 1999 and 2008. He is Editor-in-Chief of the Journal of Cancer Policy, and national cancer advisor to a number of governments. He has worked for many years as well on biosecurity and biological counterproliferation issues in both civilian and security sectors, including Ebola outbreaks in West Africa & DR Congo and most recently COVID-19 pandemic.

Dr. Sullivan is an NCD advisor to the WHO, a member of the National Cancer Grid of India and civil-military advisor to Save the Children, amongst many other positions.



DAVID TUVESON, MD, PHD, FAACR

Director, Cancer Center and Roy J. Zuckerberg Professor
Cold Spring Harbor Laboratory
Chief Scientist, *Lustgarten Foundation*
President, *AACR*

David Tuveson is Director of the NCI-designated Cancer Center at the Cold Spring Harbor Laboratory, and the Roy J. Zuckerberg Professor of Cancer Research. Dr. Tuveson is also the 2021-2022 President of the American Association for Cancer Research, and the Chief Scientist of the Lustgarten Foundation for Pancreatic Cancer Research. Dr. Tuveson obtained a bachelor's degree in chemistry at M.I.T., followed by MD and PhD degrees at Johns Hopkins. Dr. Tuveson was a medical resident at Brigham and Women's Hospital and a medical oncology fellow at Dana-Farber/Harvard Cancer Center.

During his post-doctoral years in Boston, Dr. Tuveson co-developed KIT inhibitors for gastrointestinal stromal tumors with George Demetri. Simultaneously, he generated several widely-used mouse cancer models with Tyler Jacks. As an independent investigator, his lab developed the first mouse models of ductal pancreatic cancer at the University of Pennsylvania. Subsequently, Dr. Tuveson was recruited to the University of Cambridge where his lab identified poor drug delivery as a barrier for therapeutic efficacy in pancreatic cancer. He was then recruited to CSHL as the Deputy Director of the Cancer Center and to serve as Director of Research for the Lustgarten Foundation. At CSHL, his lab co-developed pancreatic organoid cancer models with Hans Clevers, and made a series of observations regarding cancer fibroblasts, redox regulation, pancreatitis, and the Ras pathway. His awards include the Rita Allen Scholarship, the Jan Waldenström Award and the Hamdan Award. He is a Fellow of the AACR Academy, and a member of the ASCI and AAP.



KIMYATTA WASHINGTON, MHSA

Vice President, Oncology Services, RWJBarnabas Health, Central Region, and Rutgers Cancer Institute of New Jersey

Kimyatta began her professional career at Duke University Health System as an Administrative Fellow. She spent the second year of the fellowship exclusively in the cancer program beginning her career in oncology services. After five years with Duke as the administrative manager for oncology services, Kimyatta worked at Medstar Georgetown University Hospital where she served as the Director for the practice and clinical operations for the Georgetown Lombardi Comprehensive Cancer Center. In this role she led a host of operational initiatives to improve clinic wait times, access to care, and patient satisfaction.

Kimyatta joined RWJBarnabas Health in 2015 as the Assistant Vice President for Cancer Services at Robert Wood Johnson University Hospital. In 2017, she was promoted to Vice President and Director where she oversaw the operations for both the hospital and the outpatient practice at Rutgers Cancer Institute of New Jersey. Most recently, Kimyatta expanded her scope to include coordination of cancer services for the health system's central region inclusive of the New Brunswick, Somerset, and Hamilton campuses. Kimyatta is currently a member of the steering committee responsible for the design and operation of the new RWJBarnabas Health/Rutgers Cancer Institute's Jack and Sheryl Morris Cancer Center, the state's first freestanding cancer hospital.

Kimyatta received her bachelor of science in health policy and administration from the University of North Carolina at Chapel Hill School of Public Health and a master of health services administration (MHSA) from the University of Michigan School of Public Health.



CC&K 2022



Meyer Consulting is an international health care consulting and recruiting firm that brings leading experts together in collaborative settings to build better health care solutions.



MEYER CONSULTING

Phone (406) 531.5505

Fax (480) 614.5660

Website www.meyerconsultinginc.com

CORPORATE OFFICE

Meyer Consulting, LLC

5665 N. Scottsdale Road, Suite 110

Scottsdale, AZ 85250